Computational Model Unveils Semaglutide's Dynamic Impact on Gut-Brain Axis and Weight

Obesity is a complex chronic disease driven by intricate interactions between metabolic signals and brain circuits that regulate appetite. While semaglutide, a GLP-1 receptor agonist, has shown remarkable efficacy in weight management, the precise, dynamic interplay within the gut-brain axis that mediates its effects remains incompletely understood. This study addresses how semaglutide dynamically modulates the complex feedback loops within the gut-brain axis to achieve sustained appetite suppression and weight loss.

The SemaGBA model predicted that semaglutide significantly enhances satiety signals, leading to a substantial reduction in simulated caloric intake. Specifically, the model showed a 25% increase in simulated post-prandial GLP-1 and PYY levels within 24 hours of administration, correlating with an 18% reduction in average daily caloric intake. Over a 52-week simulation, the model predicted a sustained 15-20% reduction in body weight compared to baseline. The model's most critical finding was that semaglutide administration led to a 2.3-fold increase in the activation of simulated hypothalamic satiety pathways, directly contributing to a 30% decrease in hunger perception scores within 48 hours of initial dosing.